ProCE Banner Activity

CME

The Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2019

Multimedia
Watch this on-demand Webcast from our live symposium to review the latest clinical data and expert perspectives on using biomarkers to select therapy for your patients with solid tumors.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: July 11, 2019

Expiration: July 10, 2020

No longer available for credit.

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Giuseppe Giaccone

Giuseppe Giaccone, MD, PhD

Chief, Medical Oncology Branch
CCR, National Cancer Institute
Bethesda, Maryland

Axel Grothey

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Array BioPharma

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Foundation Medicine

Genentech TEXT Only

Loxo Oncology

Merck Oncology

Puma Biotechnology, Inc.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply predictive biomarkers to guide therapeutic decisions in patients with cancer
  • Evaluate the available data and expert recommendations to determine which biomarkers should be tested in your patients with cancer
  • Explain to patients the need for an additional biopsy to test for appropriate biomarkers in cases where the initial biopsy sample was insufficient or if the biomarker status was previously unknown
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received funds for research support from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho; consulting fees from Amgen, Bayer, Caris, Celgene, Genentech, Indivumed, Merck, and Taiho; and fees for non-CME services from Amgen, Bayer, Caris, Celgene, Genentech, Merck, and Taiho.

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, Armo, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech, GlaxoSmithKline, Immunocore, ImmunoGen, Incyte, Ignyta, Jacobio, Janssen, Leap, Lilly, Loxo, Karyopharm, Kolltan, MabVax, MedImmune, Medpacto, Merck, Mirati, Merrimack, Millennium, Moderna, Novartis, Onyx, Peleton, Pfizer, Phosplatin, Principa, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; has received consulting fees paid to his institution from Ignyta, Leap, Loxo, and Moderna; and has received consulting fees from Bayer, Guardant, Loxo, and Pfizer.

Giuseppe Giaccone, MD, PhD

Chief, Medical Oncology Branch
CCR, National Cancer Institute
Bethesda, Maryland

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Axel Grothey, MD, has disclosed that he has received consulting fees paid to his institution from Array, Bayer, Boston Biomedicals, Caris Life Sciences, Daiichi, and Roche/Genentech; funds for travel, accommodations, and/or expenses from Array, Bayer, Roche/Genentech; and funds for research support paid to his institution from Array, Bayer, Bristol-Myers Squibb, Daiichi, Genentech, and Merck.

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca/MedImmune, Caris, Celgene, Merrimack, Perthera, RenovoRx, and Sirtex; has ownership interest in Perthera (< 5% stock); has received fees for non-CME/CE services from Caris and Sirtex; has received funds for travel, accommodations, and/or expenses from AstraZeneca/MedImmune, Caris, Perthera, and Sirtex; and has received funds for research support paid to his institution from Armo, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Calithera, Celgene, Celldex, Curegenix, FibroGen, Genentech, Gilead Sciences, GlaxoSmithKline, Halozyme, Karyopharm, MedImmune, Merck, Novartis, Regeneron, Pfizer, Pharmacyclics, and Tesaro.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 11, 2019, through July 10, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating biomarkers to personalize cancer care.